Tian Yuan Hong Kong team assisted 160 Health International Limited (stock code: 02656.HK) (“Health 160”) in completing its initial public offering and listing on the Main Board of the Hong Kong Stock Exchange on September 17, 2025.

As a leading pharmaceutical and healthcare product wholesaler and a benchmark enterprise in integrated digital healthcare services in China, Health160 has built China's largest digital healthcare service platform. Whether considering the number of appointments registered on the platform in 2024, or the number of partner hospitals and connected medical personnel as of December 31, 2024, Health160 consistently ranks first among similar platforms in China. Adhering to its core mission of "delivering the power of love and making health simpler," Health160 is committed to creating China's leading integrated online and offline healthcare service portal. Through innovative business models driven by both "pharmaceutical and healthcare product sales" and "digital healthcare solutions," Health160's service network covers more than 260 cities including Shenzhen, Beijing, Shanghai, and Guangzhou, connecting over 44,600 healthcare institutions nationwide (including more than 3,000 tertiary hospitals) and over 900,000 medical personnel, building a convenient and efficient health protection barrier for over 55.2 million registered users.

In this IPO project, Tian Yuan Hong Kong team served as Health160 's Hong Kong legal counsel and drafted the prospectus. Leveraging its profound insights into the digital healthcare industry and precise understanding of overseas capital market rules, the team successfully helped the company showcase its core strategic value. Their professional expertise and responsible approach earned high praise and unanimous recognition from Health160 and various intermediaries. Health160's successful IPO fully demonstrates Tian Yuan Hong Kong's outstanding ability to provide one-stop, high-quality, industry-customized legal solutions in a complex regulatory environment, further solidifying and enhancing its leading position in the intersection of medical technology and capital markets.

In this project, the Tian Yuan Hong Kong team was led by Managing Partner Nan Li, with the assistance of Partners Isabelle Wu and Jora Guo, as well as lawyers Joseph Chen, Angela Huang, Jing Zhou, and Tongtong Ji.